EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSFHEG00000010740
Gene Symbol: PIK3R5
4 Cross references
184 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSFHEG00000003498
Gene Symbol: PIK3R5
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSFHEG00000019383
Gene Symbol: PIK3R1
1 Cross references
197 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSFHEG00000022930
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSFHEG00000018839
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasma Kallikrein

Ensembl ID : ENSFHEG00000003834
Gene Symbol: LOC105916752
2 Cross references
205 Possible Orthologues:

Plasminogen

Ensembl ID : ENSFHEG00000009209
Gene Symbol: PLG
3 Cross references
255 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSFHEG00000007325
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSFHEG00000006850
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSFHEG00000019250
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSFHEG00000014326
Gene Symbol: PDGFRB
3 Cross references
199 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSFHEG00000016512
Gene Symbol: LOC105922340
2 Cross references
174 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).